- Home
- SWVL vs LSTA Comparison
SWVL vs LSTA Comparison
Compare SWVL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWVL | LSTA |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 20.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SWVL | LSTA |
|---|---|---|
| Price | $2.20 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 8.3K | ★ 23.9K |
| Earning Date | 09-08-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,329,423.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.10 | $1.81 |
| 52 Week High | $7.20 | $4.20 |
Technical Indicators
Market Signals| Indicator | SWVL | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 43.94 |
| Support Level | $2.20 | $1.97 |
| Resistance Level | $2.38 | $2.15 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 0.00 | 46.87 |
Price Performance
Historical ComparisonAbout SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.